GlassScriptPhysician profile
Laura Ann Eiseman
NPI 1447565296
$4,362.78
in general payments reported to CMS, 2019-2025
40 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what 86% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $562 · 2022: $686 · 2023: $1,097 · 2024: $945 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,115.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $401.25 | 2021-2025 | |
| Amgen INC. | $336.96 | 2022-2025 | Evenity, Otezla, Repatha |
| Glaxosmithkline, LLC. | $325.04 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $300.82 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $262.94 | 2021-2025 | Verquvo, Gardasil 9, Vaxneuvance |
| Axsome Therapeutics, INC. | $239.66 | 2024-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $218.47 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $200.74 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $196.45 | 2021-2025 | Spravato |
| Antares Pharma, INC. | $193.70 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.34 | 2021-2025 | Jardiance, Ofev |
| Otsuka America Pharmaceutical, INC. | $157.68 | 2023-2025 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $150.03 | 2021-2025 | Austedo Xr, Airduo Digihaler |
| Corcept Therapeutics | $115.83 | 2023-2025 | Korlym |
| Lilly USA, LLC | $114.17 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $82.86 | 2021-2025 | |
| Astellas Pharma US INC | $76.13 | 2022-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $74.11 | 2023-2025 | |
| Dexcom, INC. | $66.81 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.59 | 2021-2025 | Xifaxan, Trulance |
| Sanofi Pasteur INC. | $58.01 | 2022-2025 | |
| Exact Sciences Corporation | $54.80 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $50.08 | 2022-2023 | Vyepti |
| Esperion Therapeutics, INC. | $48.62 | 2021-2024 | Nexletol |
| Dynavax Technologies Corporation | $42.65 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $41.20 | 2024-2025 | Camzyos |
| Abbott Laboratories | $35.40 | 2022-2025 | Freestyle Libre 2 |
| Clarus Therapeutics INC. | $31.66 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.17 | 2021-2022 | |
| Shield Therapeutics INC | $21.64 | 2023 | Accrufer |
| Biogen, INC. | $21.03 | 2024 | Skyclarys |
| Organon LLC | $20.51 | 2025 | Nexplanon |
| Halozyme INC | $18.62 | 2023 | |
| Vivus LLC | $18.48 | 2021 | |
| Corium, LLC | $18.29 | 2023 | Azstarys |
| Kowa Pharmaceuticals America, INC. | $17.15 | 2021 | |
| Eisai INC. | $17.13 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.69 | 2022 | |
| Tms Neurohealth Centers INC. | $15.94 | 2025 | Tms Neurohealth Centers INC. |
| Endo Pharmaceuticals INC. | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Eiseman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.